Serum Soluble ST2 Is a Valuable Prognostic Biomarker in Patients With Acute Heart Failure.

ABSTRACT:

Background

This study aimed to investigate the clinical utility of different soluble suppression of tumorigenicity 2 (sST2) levels in assessing the severity and prognosis of patients with acute heart failure (AHF).

Methods

This was a prospective cohort study. Three hundred and thirty-one consecutively enrolled AHF patients from March 2018 to November 2019 were divided into 3 subgroups according to sST2 levels: T1 (1.15-7.70 ng/ml; N = 110), T2 (7.71-17.24 ng/ml; N = 111), and T3 (17.26-47.42 ng/ml; N = 110). The patients were followed up for a median period of 21.0 months for the development of the primary endpoint. Cox proportional hazards model was performed to evaluate the prognostic value of sST2 for the clinical outcomes.

Results

The mean age

SUBMITTER: Wang Z 

PROVIDER: S-EPMC8863653 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature